| Literature DB >> 22185229 |
Esayas K Gudina1, Solomon T Amade, Fessahaye A Tesfamichael, Rana Ram.
Abstract
BACKGROUND: Sub-Saharan Africa is currently enduring the heaviest global burden of diabetes and diabetes care in such resource poor countries is far below standards. This study aims to describe the gaps in the care of Ethiopian diabetic patients at Jimma University Specialized Hospital.Entities:
Year: 2011 PMID: 22185229 PMCID: PMC3260211 DOI: 10.1186/1472-6823-11-19
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Background characteristic of diabetic patients on follow-up at JUSH, November 2009
| Characteristics | Frequency | % |
|---|---|---|
| Age (years) | ||
| 15 - 34 | 62 | 18.8 |
| 35 - 64 | 212 | 64.4 |
| ≥ 65 | 55 | 16.7 |
| Gender | ||
| Male | 195 | 59.3 |
| Female | 134 | 40.7 |
| Occupation | ||
| Unemployed | 115 | 35.0 |
| Farmer | 93 | 28.3 |
| Employed (paid work) | 106 | 32.2 |
| Student | 15 | 4.6 |
| Literacy status | ||
| Illiterate | 112 | 34.0 |
| Non-formal education | 14 | 4.3 |
| Elementary | 105 | 31.9 |
| High school | 57 | 17.3 |
| Above high school | 41 | 12.5 |
| Type of diabetes | ||
| Type 1 | 117 | 35.6 |
| Type 2 | 212 | 64.4 |
| Family history of diabetes | ||
| Yes | 67 | 20.4 |
| No | 262 | 79.6 |
| Duration since diagnosis (years) | ||
| 1-5 | 157 | 47.7 |
| 6-10 | 106 | 32.2 |
| ≥ 11 | 66 | 20.1 |
| Blood glucose on each visits | ||
| Not done | 5 | 1.5 |
| FBS | 312 | 94.8 |
| RBS | 12 | 3.6 |
| Access for SMBG | ||
| Yes | 18 | 5.5 |
| No | 311 | 94.5 |
| Access for drugs | ||
| Free | 321 | 97.9 |
| Paid | 7 | 2.1 |
RBS - random blood sugar, SMBG - self monitoring of blood glucose, FBS - fasting blood sugar
*One patient was not taking any glucose lowering agent and was not included.
Patterns of glycaemic management among diabetic patients at JUSH, November 2009
| Glycemic managements | Type 1 DM | Type 2 DM | Total | |||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| Initial management | ||||||
| MNT | 4 | 3.4 | 14 | 6.6 | 18 | 5.5 |
| OGLA | 15 | 12.8 | 188 | 88.7 | 203 | 61.7 |
| Insulin | 98 | 83.8 | 9 | 4.2 | 107 | 32.5 |
| Herbal treatment | 0 | 0.0 | 1 | 0.5 | 1 | 0.3 |
| Current management | ||||||
| MNT alone | 0 | 0 | 1 | 0.5 | 1 | 0.3 |
| Insulin alone | 109 | 93.2 | 61 | 28.8 | 170 | 51.7 |
| Insulin and OGLA | 7 | 6.0 | 6 | 2.8 | 13 | 4.0 |
| Single OGLA | 0 | 0.0 | 69 | 32.5 | 69 | 21.0 |
| Combination OGLA | 1 | 0.8 | 75 | 35.4 | 76 | 23.1 |
| Initiation of pharmacologic treatment | ||||||
| At the time of diagnosis | 112 | 95.7 | 184 | 86.8 | 296 | 90.0 |
| Later on | 5 | 4.3 | 28 | 13.2 | 33 | 10.0 |
| FBS (mg/dl) | ||||||
| < 70 | 0 | 0.0 | 2 | 1.0 | 2 | 0.6 |
| 70-130 | 24 | 22.4 | 58 | 28.3 | 82 | 26.3 |
| > 130 | 83 | 77.6 | 145 | 70.7 | 228 | 73.1 |
| Doses of drugs ( | ||||||
| Insuline - IU | 52.4 ± 20.1 | 45.0 ± 15.8 | 49.7 ± 19.0 | |||
| Glibenclamide - mg/dl | 20.0 ± 0 | 15.2 ± 6.5 | 15.3 ± 6.5 | |||
| Metformine- mg/dl | 625.0 ± 231.5 | 882.0 ± 406.1 | 860.8 ± 400.1 | |||
MNT - medical nutritional therapy, OGLA -oral glucose lowering agent, FBS - fasting blood sugar
Adequacy of glycaemic management in diabetic patients on follow-up at JUSH, November 2009
| FBS | ||||||
|---|---|---|---|---|---|---|
| Treatment categories | Average FBS, mg/dl | ≤ 130 mg/dl | > 130 mg/dl | P-value | ||
| N | % | N | % | |||
| Pharmacotherapeutic options | ||||||
| Insulin alone | 170.8 | 37 | 23.6 | 120 | 76.4 | |
| Insulin and OGLA | 190.3 | 3 | 23.1 | 10 | 76.9 | 0.0006 |
| One OGLA | 152.7 | 28 | 41.8 | 39 | 58.2 | |
| Both OGLA | 188.7 | 15 | 22.4 | 59 | 77.6 | |
| Doses of drugs | ||||||
| Insulin | ||||||
| < 1IU/Kg/d | 167.7 | 36 | 25.5 | 105 | 74.5 | 0.175 |
| | 194.5 | 4 | 13.8 | 25 | 86.2 | |
| Glibenclamide (G) | ||||||
| < 20 mg/d | 149.4 | 30 | 50.0 | 30 | 50.0 | 0.0001 |
| | 190.0 | 11 | 15.1 | 62 | 84.9 | |
| Metformin(M) | ||||||
| < 1000 mg/d | 163.1 | 15 | 38.5 | 24 | 61.5 | 0.001 |
| | 204.3 | 5 | 8.9 | 52 | 91.1 | |
| Glibenclamide + metformin | ||||||
| G < 20 mg/d or M < 1000 mg/d | 168.1 | 12 | 36.4 | 21 | 63.6 | 0.005 |
| G | 203.3 | 4 | 9.5 | 38 | 90.5 | |
| Modification of glycaemic treatment during the last 3 visits | ||||||
| Yes | 16 | 19.0 | 70 | 30.7 | ||
| No | 68 | 81.0 | 158 | 69.3 | ||
In 13 of these patients treatment modification was for low FBS or symptoms of hypoglycemia.
Patterns of Hypertension management in diabetic patients on follow-up at JUSH, November 2009
| Characteristics | Frequency | (%) |
|---|---|---|
| History of hypertension | ||
| Yes | 146 | 44.4 |
| No | 183 | 55.6 |
| Pharmacologic treatment for hypertension | ||
| Yes | 130 | 89.0 |
| No | 16 | 11.0 |
| Proportion with hypertension by diabetes type | ||
| Type 1 ( | 30 | 20.5 |
| Type 2 ( | 116 | 79.5 |
| BP in mmHg | ||
| < 130/80 | 118 | 35.9 |
| 130/80 to < 140/90 | 110 | 33.4 |
| 140/90 to < 160/100 | 81 | 24.6 |
| ≥ 160/100 | 20 | 6.1 |
| Antihypertensive agents | ||
| HCT | 16 | 12.3 |
| ACE inhibitor | 110 | 84.6 |
| Beta blocker | 10 | 7.7 |
| Calcium channel blocker | 21 | 16.2 |
| Others | 11 | 8.4 |
| Option of drugs | ||
| Single agent | 95 | 73.1 |
| Two drugs | 32 | 24.6 |
| Three drugs | 3 | 2.3 |
BP - blood pressure, HCT - hydrochlorothiazide, ACE - angiotensin converting enzyme
Adequacy of Hypertension management in diabetic patients on follow-up at JUSH, November 2009
| BP (in mmHg) | |||||
|---|---|---|---|---|---|
| Characteristics | < 130/80 | ≥ 130/80 | P value | ||
| N | % | N | % | ||
| History of hypertension | |||||
| Yes | 10 | 6.8 | 136 | 93.2 | 0.0001 |
| No | 108 | 59.0 | 75 | 41.0 | |
| Pharmacologic treatment of hypertension | |||||
| Yes | 9 | 6.9 | 121 | 93.1 | 0.92 |
| No | 109 | 54.8 | 90 | 45.2 | |
| Treatment modification of the last 3 visits | |||||
| Yes | 3 | 2.5 | 46 | 21.8 | 0.599 |
| No | 115 | 97.5 | 165 | 78.2 | |
Clinical follow-up patterns of diabetic patients at JUSH, November 2009
| Characteristics | Frequency | (%) |
|---|---|---|
| Weight measurements during the last 3 visits | 224 | 68.1 |
| Evaluation for DM neuropathy | 31 | 9.4 |
| Diabetic eye evaluation ever | 141 | 42.9 |
| Recent finding of eye evaluation | ||
| Normal | 36 | 25.5 |
| Cataract/glaucoma | 14 | 9.9 |
| Diabetic retinopathy | 26 | 18.4 |
| No documentation | 65 | 46.1 |
| RFT | 97 | 29.5 |
| Urinalysis | 216 | 65.6 |
| Lipid profile | 16 | 4.9 |
| ECG | 13 | 4.0 |
| Echocardiography | 9 | 2.7 |
| Ultrasound of the kidneys | 13 | 4.0 |
| Aspirin | 46 | 14.0 |
| Lipid lowering drugs | 9 | 2.7 |
| DKA | 28 | 71.8 |
| Hypoglycemia | 2 | 5.1 |
| Ulcer or gangrene of extremities | 5 | 12.8 |
| Stroke | 2 | 5.1 |
| Other | 2 | 5.1 |
| DKA | 44 | 40.7 |
| Peripheral neuropathy | 27 | 25.0 |
| Diabetic retinopathy | 25 | 23.1 |
| Diabetic foot ulcer | 11 | 10.2 |
| Stroke/IHD | 12 | 11.1 |
| Others | 7 | 6.5 |
| Blurring of vision | 106 | 32.2 |
| Numbness | 100 | 30.4 |
| Polysymptoms | 74 | 22.5 |
| Easy fatigability | 71 | 21.6 |
| Breathlessness/Chest pain/Body swelling | 51 | 15.5 |
| Foot ulcer/delayed wound healing | 22 | 6.7 |
| Impotence | 15 | 4.6 |
| Others | 21 | 6.4 |
RFT - renal function test, ECG - electrocardiography, DKA - diabetic ketoacidosis, IHD - ischemic heart disease